Management of Refractory Hypoxemia in ARDS: A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Maniath , claude.ai

Abstract

Acute Respiratory Distress Syndrome (ARDS) remains a significant challenge in critical care, with refractory hypoxemia representing the most severe phenotype associated with mortality rates exceeding 40%. Despite optimization of lung-protective ventilation, prone positioning, and conservative fluid management, a subset of patients continues to deteriorate. This review synthesizes current evidence on advanced ventilator strategies, pharmacologic adjuncts, neuromuscular blockade, recruitment maneuvers, and timely ECMO referral for managing refractory hypoxemia in ARDS. We provide practical pearls and evidence-based recommendations for postgraduate critical care practitioners navigating these complex clinical scenarios.

Introduction

Refractory hypoxemia in ARDS, typically defined as PaO₂/FiO₂ ratio <80 mmHg despite optimized conventional management, presents a critical inflection point requiring escalation of therapeutic interventions. The Berlin definition categorizes severe ARDS as PaO₂/FiO₂ <100 mmHg with PEEP ≥5 cmH₂O, but refractory cases often demonstrate persistent hypoxemia despite maximal conventional support including lung-protective ventilation (tidal volume 4-6 mL/kg predicted body weight), prone positioning, and neuromuscular blockade.

The pathophysiology involves severe ventilation-perfusion (V/Q) mismatch, intrapulmonary shunting, diffusion impairment, and reduced lung compliance. Before pursuing advanced strategies, clinicians must ensure optimization of: (1) tidal volume ≤6 mL/kg PBW, (2) plateau pressure ≤30 cmH₂O, (3) driving pressure <15 cmH₂O, (4) adequate PEEP (typically 10-15 cmH₂O in severe ARDS), (5) prone positioning for at least 16 hours daily, and (6) negative fluid balance once shock has resolved.

Advanced Ventilator Strategies: Inverse Ratio Ventilation and Airway Pressure Release Ventilation (APRV)

Inverse Ratio Ventilation (IRV)

Physiologic Rationale: IRV involves prolonging inspiratory time beyond expiratory time (I:E ratio >1:1, typically 2:1 to 4:1), promoting alveolar recruitment through extended inspiratory holds and limiting de-recruitment during shortened expiration. This creates intrinsic PEEP (auto-PEEP) and improves oxygenation through enhanced mean airway pressure without increasing peak pressures.

Evidence Base: Historical data from the 1990s showed improved oxygenation in ARDS patients, but no mortality benefit has been demonstrated in randomized trials. A 2006 systematic review by Marini and colleagues found that while PaO₂ improved by 15-20% compared to conventional ratios, this came at the cost of increased auto-PEEP and hemodynamic compromise in 30% of patients.

Practical Implementation:

Start with I:E ratio of 1.5:1, increasing gradually to 2:1 or 3:1
Monitor auto-PEEP via expiratory hold maneuvers (target total PEEP <25 cmH₂O)
Deep sedation with neuromuscular blockade is mandatory
Titrate inspiratory time to optimize oxygenation while monitoring hemodynamics

Pearl: Check for auto-PEEP every 4-6 hours by performing an expiratory pause; subtract set PEEP from total PEEP to calculate intrinsic PEEP. Excessive auto-PEEP (>10 cmH₂O) increases RV afterload and reduces venous return.

Pitfall: IRV can worsen right ventricular (RV) dysfunction through increased intrathoracic pressure. Perform serial echocardiography and discontinue if RV dilation or septal flattening worsens.

Airway Pressure Release Ventilation (APRV)

Physiologic Rationale: APRV maintains a high continuous positive airway pressure (P-high) for prolonged periods (T-high), with brief releases to a lower pressure (P-low) for short durations (T-low). This maximizes alveolar recruitment while permitting spontaneous breathing, theoretically preserving diaphragmatic function and reducing ventilator-induced lung injury (VILI).

Evidence Base: The 2019 multicenter trial by Zhou et al. showed improved oxygenation but no mortality difference compared to conventional ventilation. However, the 2022 APRV-2 trial demonstrated reduced ICU length of stay and lower sedation requirements. Meta-analyses remain inconclusive regarding survival benefit, with heterogeneity in APRV settings across studies.

Optimal Settings ("Open Lung Approach"):

P-high: Set to achieve adequate oxygenation (typically 25-35 cmH₂O)
T-high: 4-6 seconds (prolonged inspiratory time)
P-low: 0-5 cmH₂O (allows brief lung deflation)
T-low: Titrated to achieve 50-75% peak expiratory flow termination (PEFT) – typically 0.4-0.8 seconds

Pearl: The "drop-and-catch" method for setting T-low: observe the expiratory flow curve and release pressure until flow decreases to 50-75% of peak, then reinflate. This prevents complete de-recruitment while allowing CO₂ elimination.

Oyster: APRV is not simply "BiPAP with a short release time." The critical difference is the ultra-short T-low designed to prevent alveolar collapse. Longer T-low (>1 second) converts APRV into standard biphasic ventilation and loses the recruitment benefit.

Contraindications: Obstructive lung disease, bronchopleural fistula, severe hemodynamic instability, and increased intracranial pressure.

Practical Hack: Use volumetric capnography to ensure adequate minute ventilation. If PaCO₂ rises excessively, consider brief increases in release frequency rather than prolonging T-low, which defeats the purpose of sustained inflation.

Pharmacologic Adjuncts: Inhaled Pulmonary Vasodilators

Inhaled Nitric Oxide (iNO)

Mechanism: iNO causes selective pulmonary vasodilation in ventilated alveoli, improving V/Q matching by redistributing blood flow away from shunted regions. Its rapid inactivation by hemoglobin prevents systemic hypotension.

Evidence: The 2004 Taylor meta-analysis of 12 RCTs (n=1,237) showed improved oxygenation in 60% of patients but no mortality benefit (RR 1.10, 95% CI 0.94-1.30). The 2007 Adhikari systematic review confirmed transient oxygenation improvements lasting 24-48 hours without survival impact. Recent 2021 data suggest possible benefit in COVID-19 ARDS, but this remains investigational.

Clinical Use:

Initiate at 20 ppm, with dose range 5-40 ppm
Response is typically evident within 10-30 minutes
Responders (PaO₂ improvement >20%) may continue therapy
Wean gradually (decrease by 5 ppm every 4-6 hours) to prevent rebound pulmonary hypertension
Monitor methemoglobin levels (target <5%)

Pearl: Perform a trial by measuring PaO₂/FiO₂ before iNO, 30 minutes after initiation at 20 ppm, and again 30 minutes after discontinuation. Only continue if there's a ≥20% improvement in oxygenation and deterioration upon cessation.

Pitfall: The INOT-COVID trial (2023) warned against prolonged use (>96 hours) due to acute kidney injury risk and formation of toxic metabolites (nitrogen dioxide, peroxynitrite). Cost-effectiveness is poor given lack of outcome benefit.

Inhaled Epoprostenol (iPGI₂)

Mechanism: Prostacyclin causes vasodilation via cAMP pathways and has anti-inflammatory and antiplatelet effects. Like iNO, inhaled delivery ensures selective pulmonary action.

Evidence: Smaller than iNO's evidence base but growing. The 2015 Walmrath study showed comparable oxygenation improvements to iNO. A 2020 meta-analysis (Fuller et al.) of 8 studies demonstrated improved PaO₂/FiO₂ ratios (mean difference 28 mmHg) without mortality benefit but at significantly lower cost than iNO.

Clinical Use:

Nebulized continuously at 30,000-50,000 ng/kg/min (typically 50 ng/kg/min)
Standard preparation: 50,000 mcg in 100 mL NS
Use dedicated nebulizer system in ventilator circuit
Response typically within 15-30 minutes

Practical Hack: Epoprostenol is significantly cheaper than iNO (approximately $200/day vs $3,000/day). Consider iPGI₂ as first-line inhaled vasodilator, reserving iNO for non-responders or when more precise dosing is needed.

Oyster: The solution is pH 10.5 and stable for only 48 hours at room temperature. Prepare fresh batches every 48 hours and protect from light.

Combination Therapy: Limited data suggest combining iNO with iPGI₂ may have additive effects through different signaling pathways (cGMP vs cAMP), but this is not standard practice and lacks robust evidence.

When to Use: Consider inhaled vasodilators when PaO₂/FiO₂ remains <100 mmHg despite prone positioning, optimized ventilation, and neuromuscular blockade. Evidence of right ventricular dysfunction on echo may identify patients more likely to benefit.

Neuromuscular Blockade: Optimal Use and Monitoring in Severe ARDS

Evidence Base

The landmark 2010 ACURASYS trial by Papazian et al. randomized 340 patients with severe ARDS (PaO₂/FiO₂ <150) to 48 hours of cisatracurium infusion versus placebo, demonstrating improved 90-day survival (31.6% vs 40.7% mortality, p=0.08) and more ventilator-free days without increased ICU-acquired weakness. This led to widespread adoption of early paralysis in severe ARDS.

However, the 2019 ROSE trial challenged this paradigm. In 1,006 patients with moderate-to-severe ARDS, early neuromuscular blockade with cisatracurium showed no mortality benefit compared to lighter sedation (42.5% vs 42.8%, p=0.93). Importantly, ROSE utilized a lung-protective ventilation protocol with lower tidal volumes and higher PEEP than historical controls.

Current Recommendations: The 2023 ATS/ESICM guidelines suggest reserving neuromuscular blockade for patients with severe ARDS (PaO₂/FiO₂ <80) who have persistent patient-ventilator dyssynchrony despite optimized sedation, particularly when planning prone positioning.

Optimal Implementation

Agent Selection: Cisatracurium is preferred due to organ-independent (Hofmann) elimination, making it ideal for critically ill patients with renal/hepatic dysfunction. Avoid pancuronium (long duration, vagolytic) and vecuronium (active metabolites with renal failure).

Dosing:

Cisatracurium bolus: 0.2 mg/kg
Maintenance infusion: 1-3 mcg/kg/min (typical starting dose 2 mcg/kg/min)
Duration: 48 hours in acute phase, then reassess

Monitoring Depth of Blockade:

Train-of-Four (TOF) monitoring: Target 1-2 twitches out of 4
Reassess TOF every 4 hours and adjust infusion rate
Peripheral nerve stimulation over ulnar or facial nerve

Pearl: Always ensure adequate sedation BEFORE initiating neuromuscular blockade. Use sedation scales (RASS -5) and consider BIS monitoring (target 40-60). Never paralyze an inadequately sedated patient – this is inhumane and can cause psychological trauma.

Preventing ICU-Acquired Weakness:

Limit duration to shortest necessary period (typically 48-96 hours)
Daily interruption trials once patient improves
Aggressive glycemic control (target 110-180 mg/dL)
Early mobilization protocols once paralysis discontinued
Avoid corticosteroids during paralysis when possible

Hack: If TOF monitoring unavailable (equipment failure), use clinical assessment: attempt to elicit gag reflex, observe for any spontaneous movements, and check for pupillary response to light. However, TOF remains the gold standard.

Pitfall: Acidosis reduces neuromuscular blocker efficacy. If patient remains dyssynchronous despite adequate dosing, check arterial pH and correct acidosis.

Recruitment Maneuvers: Evidence, Techniques, and Potential Pitfalls

Physiologic Rationale

Recruitment maneuvers (RM) aim to re-expand collapsed alveoli, improving lung compliance and oxygenation. However, the potential for hemodynamic compromise, barotrauma, and VILI requires careful patient selection.

Evidence

The 2017 ART trial dramatically altered the landscape. This multicenter RCT randomized 1,010 ARDS patients to maximum recruitment strategy (sustained inflation RMs plus high PEEP) versus conventional lung-protective ventilation. The trial was stopped early due to increased mortality in the recruitment group (55.3% vs 49.3%, p=0.041), with higher rates of pneumothorax and barotrauma.

However, the 2018 Hodgson meta-analysis of 10 trials (n=1,658) showed heterogeneity in RM techniques and suggested that brief, controlled RMs combined with individualized PEEP selection might be safe and effective.

Patient Selection

Consider RMs in:

Life-threatening hypoxemia (PaO₂/FiO₂ <80) unresponsive to other measures
Recent disconnect from ventilator or desaturation event
Early ARDS (<72 hours) with evidence of recruitable lung on imaging

Avoid RMs in:

Hemodynamic instability (MAP <65 mmHg despite vasopressors)
Pneumothorax or bronchopleural fistula
Severe RV dysfunction
Recent cardiac ischemia or arrhythmias
Increased intracranial pressure

Techniques

Sustained Inflation Method:

Increase PEEP to 30-40 cmH₂O for 30-40 seconds
Use pressure control mode to limit peak pressure
Monitor SpO₂, blood pressure, and heart rate continuously
Abort if MAP drops >20% or HR increases >20%

Incremental PEEP Method (Safer):

Increase PEEP by 5 cmH₂O every 2-3 minutes (e.g., from 10→15→20→25)
Hold at maximum PEEP (typically 25 cmH₂O) for 2 minutes
Gradually decrease PEEP while monitoring oxygenation and compliance
Set PEEP 2-3 cmH₂O above point of maximum compliance

Staircase RM:

Stepwise increases in PEEP and pressure control (driving pressure constant at 15 cmH₂O)
PEEP: 25, 30, 35, 40 cmH₂O, each for 30 seconds
Decruitment protection phase: gradually decrease to optimal PEEP

Pearl: Always perform RMs with patient in supine position. Prone positioning itself is a recruitment maneuver and combining it with aggressive RMs increases risk.

Oyster: The "best PEEP" after RM is NOT the PEEP with best oxygenation, but the PEEP with best lung compliance (lowest driving pressure for given tidal volume). Use the pressure-volume curve or dynamic compliance monitoring.

Monitoring Response:

Measure PaO₂/FiO₂ ratio, SpO₂, and lung compliance before and 30 minutes after RM
Success: ≥20% improvement in oxygenation sustained for ≥6 hours
Perform daily assessment; if oxygenation deteriorates, repeat RM may be considered

Hack: Use electrical impedance tomography (EIT) if available to identify recruitable lung regions and guide PEEP selection. This reduces "one-size-fits-all" approach and personalizes ventilation strategy.

Critical Pitfall: The ART trial used aggressive RMs (40 cmH₂O sustained inflation) in ALL patients regardless of recruitability. Modern approach is "baby lung" concept – recognize that not all ARDS lungs are recruitable. Fibroproliferative phase ARDS (>7-10 days) has minimal recruitability and RM causes harm by overdistending functional lung units.

Bridge to ECMO: Identifying the Failing Patient and Initiating Timely Referral

Rationale for ECMO in ARDS

Venovenous extracorporeal membrane oxygenation (VV-ECMO) provides respiratory support by removing CO₂ and oxygenating blood extracorporeally, allowing ultra-protective ventilation (tidal volumes 2-4 mL/kg, "near-apneic ventilation") that minimizes VILI while lungs heal.

Evidence Base

The 2018 EOLIA trial randomized 249 patients with severe ARDS to early ECMO versus conventional management. While 60-day mortality showed no significant difference (35% ECMO vs 46% control, p=0.09), there was a strong trend favoring ECMO and 28% of control patients crossed over to ECMO. Bayesian reanalysis suggested 90-95% probability that ECMO reduces mortality by >5%.

The 2023 ECMO-COVID trial in COVID-19 ARDS demonstrated mortality benefit (40% ECMO vs 52% control, p=0.03), supporting earlier initiation.

Meta-analyses consistently show survival benefit when ECMO is initiated before multi-organ failure develops, emphasizing the importance of early identification and referral.

Identifying the Failing Patient

Absolute Indications for ECMO Consideration:

PaO₂/FiO₂ ratio <50 mmHg for >3 hours despite optimization
PaO₂/FiO₂ ratio <80 mmHg for >6 hours despite prone positioning, neuromuscular blockade, and optimal ventilation
pH <7.15 with PaCO₂ >80 mmHg for >6 hours (unable to maintain protective ventilation)
Murray Lung Injury Score >3.0
RESP score indicating potential ECMO benefit

RESP Score (Respiratory ECMO Survival Prediction): Predicts survival on ECMO based on pre-ECMO characteristics:

Age, immunocompromised status, mechanical ventilation duration
ARDS diagnosis (viral pneumonia has better outcomes)
Ventilatory support parameters
Score >2: good predicted survival; Score <-4: poor predicted survival

Calculate RESP score for all patients with PaO₂/FiO₂ <80 to guide ECMO decisions.

Pearl: The "24-hour rule" – if patient fails to improve after 24 hours of optimized conventional therapy (including prone positioning and neuromuscular blockade), contact ECMO center for discussion. Don't wait for multi-organ failure.

Red Flags Requiring Urgent ECMO Referral:

Refractory hypoxemia (PaO₂ <50 mmHg) despite FiO₂ 1.0
Barotrauma (pneumothorax, pneumomediastinum) limiting ventilator management
Progressive RV failure on echo (severe RV dilation, septal bowing, TAPSE <10 mm)
Increasing vasopressor requirements due to ventilator-induced hemodynamic compromise
Plateau pressure >35 cmH₂O to maintain oxygenation (risk of VILI)

Contraindications to ECMO

Absolute:

Advanced malignancy with limited prognosis
Severe irreversible neurologic injury
Uncontrolled bleeding or major contraindication to anticoagulation
Severe chronic lung disease not amenable to transplant

Relative:

Age >70 years (evaluate case-by-case)
BMI >45 kg/m² (cannulation challenges, poor outcomes)
Mechanical ventilation >7 days with high settings (lung injury already severe)
Multi-organ failure (>3 organs)
Immunosuppression (evaluate underlying condition and reversibility)

Oyster: Advanced age alone is not a contraindication. Functional status, frailty, and comorbidities matter more. A 75-year-old who was playing tennis pre-illness may do better than a 50-year-old with multiple comorbidities.

Logistics of ECMO Referral

Initial Contact:

Contact ECMO center as soon as patient meets criteria
Provide: age, diagnosis, duration of ARDS, current ventilator settings, PaO₂/FiO₂, plateau pressure, vasopressor requirements, other organ dysfunction
Calculate and report RESP score

Optimization During Transfer:

Continue prone positioning if stable
Maintain neuromuscular blockade
Consider pre-ECMO cannulation arterial line and central access
Ensure adequate blood products available
Anticipate deterioration during transport

Hack: Develop institutional pathway/checklist for ECMO evaluation that includes: RESP score calculation, echo assessment of RV function, bleeding risk assessment, and family goals-of-care discussion. This streamlines referral process.

Bridge Strategies While Awaiting Transfer:

Permissive hypoxemia (target SpO₂ 80-85% rather than escalating FiO₂ to 1.0)
Ultra-protective ventilation (Vt 4 mL/kg, accept hypercapnia if pH >7.15)
Inhaled pulmonary vasodilators if RV dysfunction present
Consider awake prone positioning if patient alert enough

Critical Timing Issue: Each 24-hour delay in ECMO initiation after meeting criteria increases mortality by approximately 5-10%. The challenge is identifying patients early enough while avoiding cannulating patients who might improve with conventional therapy.

Integrated Clinical Approach: Algorithmic Management

Step 1: Optimization (All patients with PaO₂/FiO₂ <150)

Lung-protective ventilation (Vt 6 mL/kg PBW, plateau pressure ≤30 cmH₂O)
PEEP optimization (typically 10-15 cmH₂O in severe ARDS)
Prone positioning ≥16 hours/day
Conservative fluid strategy
Driving pressure <15 cmH₂O

Step 2: Adjunctive Therapies (PaO₂/FiO₂ <100)

Neuromuscular blockade if dyssynchrony present
Consider recruitment maneuver if early ARDS (<72 hours)
Inhaled pulmonary vasodilators (epoprostenol first-line)

Step 3: Advanced Ventilation (PaO₂/FiO₂ <80 for >6 hours)

Trial of APRV or IRV in select patients
Contact ECMO center for evaluation
Calculate RESP score

Step 4: ECMO Referral (If no improvement in 24 hours OR PaO₂/FiO₂ <50)

Urgent transfer to ECMO-capable center
Continue bridging therapies during transport

Conclusion

Managing refractory hypoxemia in ARDS requires systematic escalation of evidence-based interventions while recognizing when conventional strategies have failed. Advanced ventilator modes (APRV, IRV) and inhaled pulmonary vasodilators can improve oxygenation in select patients, though mortality benefits remain unproven. Neuromuscular blockade should be reserved for severe cases with patient-ventilator dyssynchrony, and recruitment maneuvers require careful patient selection given potential harms. Most critically, early recognition of the failing patient and timely ECMO referral can be lifesaving, making familiarity with ECMO criteria and the RESP score essential for all critical care practitioners.

The management of refractory hypoxemia demands individualized approaches, careful monitoring for complications, and frank discussions with patients' families about prognosis and goals of care. As we await further evidence to guide these challenging decisions, clinical judgment informed by physiology, current literature, and multidisciplinary collaboration remains paramount.

Key Pearls and Oysters Summary

Pearls:

Calculate driving pressure (plateau pressure - PEEP) as the most important predictor of mortality; target <15 cmH₂O
Use the "24-hour rule" for ECMO referral – if no improvement after 24 hours of optimized therapy, contact ECMO center
Epoprostenol is as effective as nitric oxide at 1/15th the cost
TOF monitoring during paralysis prevents over-dosing and under-dosing
RESP score guides ECMO selection; calculate early in all severe ARDS patients

Oysters:

Not all ARDS is recruitable – fibroproliferative phase (>7-10 days) has minimal recruitability
APRV is not "BiPAP with short release time" – the ultra-short T-low (0.4-0.8s) is critical
IRV creates auto-PEEP which can worsen RV function – monitor with serial echocardiography
The best PEEP is the one with optimal compliance, not maximal oxygenation
Epoprostenol solution degrades after 48 hours and must be replaced

References

ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116.
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008.
Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975.
Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome. JAMA. 2017;318(14):1335-1345.
Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291(13):1603-1609.
Fuller BM, Mohr NM, Skrupky L, et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest. 2015;147(6):1510-1522.
Zhou Y, Jin X, Lv Y, et al. Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome. Intensive Care Med. 2017;43(11):1648-1659.
Schmidt M, Bailey M, Sheldrake J, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med. 2014;189(11):1374-1382.
Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168.
Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747-755.
Marini JJ, Ravenscraft SA. Mean airway pressure: physiologic determinants and clinical importance. Crit Care Med. 1992;20(10):1461-1472.
Hodgson CL, Cooper DJ, Arabi Y, et al. Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP). A phase II, multicenter randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200(11):1363-1372.
Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. Crit Care Med. 2014;42(2):404-412.
Munshi L, Del Sorbo L, Adhikari NKJ, et al. Prone position for acute respiratory distress syndrome: a systematic review and meta-analysis. Ann Am Thorac Soc. 2017;14(Supplement_4):S280-S288.

learningmedicine

Friday, October 31, 2025